Amit Aysola is a managing director of Wanxiang Healthcare Investments, the corporate venturing subsidiary of Wanxiang America, a US-based subsidiary of China-headquartered automotive components producer Wanxiang. The unit focuses on investments in healthcare technologies, with an emphasis on digital health. Since its inception in October 2016, Wanxiang Healthcare Investments has made 13 investments focusing on series A to C rounds.
Wanxiang Healthcare Investments made six investments in 2018, including a series E round in Livongo Health, a series B round in OM1, and in new portfolio companies such as Wiivv and Higi. The unit’s first 11 investments were in the health IT space, but Aysola decided to shift focus last year to broaden the portfolio and explore opportunities in other areas.
He said: “We accomplished this with two additional investments in the medical device space – Attune Medical and Endotronix. I am looking to continue to expand on our healthcare thesis and am now exploring opportunities in adjacent areas such as water analytics and food tech.”
Aysola has spent most of his career in healthcare. He has a master’s degree in biomedical engineering from University of Michigan but decided to approach the challenges facing the healthcare industry from a business, operations and technical perspective through his roles at Deloitte Consulting and Plan Data Management, a healthtech startup.
He added: “I transitioned into investment banking after graduating from Duke University’s Fuqua School of Business, and my last job prior to Wanxiang was as a principal at Healthcare Growth Partners, a boutique investment bank focusing solely on the health IT space.
